Amorphous Solid Dispersion of Alpha-Ketoamide Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The compound ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester has limited solubility and absorption, hindering its pharmacological effectiveness, particularly when administered orally.
Innovation Solution
A solid dispersion of the compound is created by making it amorphous in the presence of a water-soluble cellulosic polymer, such as hydroxypropyl methylcellulose, and then lyophilizing the mixture to enhance solubility and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the compound is administered in conventional form, then the administration process is simple, but the solubility and absorption are insufficient
Solution Approach 1:
The patent changes the physical state of the compound from crystalline to amorphous, fundamentally altering its dissolution properties. This phase transition enables significantly improved solubility and absorption without requiring complex delivery systems or adjuvants
Solution Approach 2:
The patent creates a composite system by combining the amorphous compound with specific excipients (such as hydroxypropyl cellulose or polyvinyl alcohol) to form a solid dispersion. This composite approach maintains formulation simplicity while achieving enhanced solubility through the synergistic interaction between the amorphous drug and the excipient matrix
2Quantity of substance
If the compound is made amorphous to improve solubility, then the solubility increases, but the storage stability may be compromised
Solution Approach 1:
The patent introduces excipients such as hydroxypropyl cellulose or polyvinyl alcohol as intermediary substances that stabilize the amorphous compound during storage. These excipients form a protective matrix that prevents molecular rearrangement and crystallization, thereby maintaining both the amorphous state and storage stability simultaneously
Solution Approach 2:
The patent creates local stability by forming a homogeneous solid dispersion where the amorphous compound is uniformly distributed within the excipient matrix. This local structural organization prevents phase separation and crystallization, allowing the amorphous form to maintain both high solubility and long-term stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly improves the solubility and oral absorption of the compound, achieving a 2-fold increase in solubility and maintaining storage stability, thereby enhancing its pharmacological effectiveness.
Implementation Method 1
dissolving a ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester drug substance and a water-soluble cellulosic polymer in a solvent, such as water/t-butyl alcohol, followed by lyophilization makes the amorphous ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino) carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester
Data Source
AI summary
A solid dispersion comprising ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester made amorphous in the presence of a water-soluble cellulosic polymer has improved storage stability. The solid dispersion also has improved solubility for an improved bioavailability.